Cristina Domínguez González — Biomedical Watch V2

Traitements3programmes

Essais2liés

Publications0liées

SourceDBlocale

Traitements

3

Molécule	Indication / population	Phase	Objectif	Pays	Résultat
doxecitine and doxribtimineThis is a Phase 2 prospective open-label treatment study of the safety and efficacy of doxecitine and doxribtimine in study participants with thymidine kinase 2 (TK2) deficiency who participated in the retrospective study MT-1621-101 \[NCT03701568\] or who were receiving nucleos(t)ide treatment and were approved by the Sponsor.	Myopathies	Phase 2	À vérifier	Spain	À vérifier
doxecitine and doxribtimineThis is a Phase 2 prospective open-label treatment study of the safety and efficacy of doxecitine and doxribtimine in study participants with thymidine kinase 2 (TK2) deficiency who participated in the retrospective study MT-1621-101 \[NCT03701568\] or who were receiving nucleos(t)ide treatment and were approved by the Sponsor.	Myopathies	Phase 2	À vérifier	United States, Israel, Spain	À vérifier
doxecitine and doxribtimineThis is a Phase 2 prospective open-label treatment study of the safety and efficacy of doxecitine and doxribtimine in study participants with thymidine kinase 2 (TK2) deficiency who participated in the retrospective study MT-1621-101 \[NCT03701568\] or who were receiving nucleos(t)ide treatment and were approved by the Sponsor.	Myopathies	Phase 2	À vérifier	Spain	À vérifier

Essais cliniques

2

Molécule	Indication / population	Phase	NCT	Titre	Statut
doxecitine and doxribtimine	Myopathies	Phase 2	NCT06754098	Doxecitin and Doxribthymine in Adult Subjects With Thymidine Kinase 2 (TK2) Deficiency	RECRUITING
doxecitine and doxribtimine	Myopathies	Phase 2	NCT03845712	An Open-Label Study of Continuation Treatment With Combination Pyrimidine Nucleosides in Patients With TK2 Deficiency	COMPLETED

Publications

0

Molécule	Indication / population	Titre	Journal	Date
Aucune publication.